Gene-Disorder Association · Article
First reported
2009
Supporting publications
2
Manually curatedApproved treatment annotated
Association Review
In brief
The association between MIR21 (MicroRNA 21) and Bladder Cancer is reported, supported by a single source.
Sources
1
Clinical variants
0
Symptoms
4
Compounds
1
Trials
126of 3,298 via MIR21 compounds
Publications
2
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Bladder Cancer
The disorder
17 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
2 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
3,298 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
2 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources
8 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access